OVCAR-4 Cells
USD 650.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Información general
| Descripción | OVCAR-4 is a human ovarian carcinoma cell line derived from an adult patient with epithelial ovarian cancer who had previously undergone combination chemotherapy. It belongs to a panel of ovarian cancer cell lines established to model clinical drug resistance and tumor heterogeneity. As part of this series, OVCAR-4 reflects characteristics of tumors exposed to chemotherapeutic agents such as cisplatin and doxorubicin, making it particularly valuable for studying mechanisms of chemotherapy response and resistance. Molecular analyses have demonstrated that OVCAR-4 exhibits detectable expression of metallothionein mRNA, a protein involved in metal ion binding and cellular detoxification pathways. Notably, exposure to cisplatin induces only a modest increase in metallothionein expression in this cell line, suggesting that while metallothionein may contribute to cellular stress responses, it is not a primary determinant of cisplatin resistance in this model. These findings highlight the complexity of drug resistance mechanisms in ovarian cancer, where multiple pathways—including drug transport, DNA repair, and intracellular detoxification - may act in parallel. OVCAR-4 is included in the NCI-60 cancer cell line panel and has been utilized in high-content phenotypic profiling studies. Fluorescence-based screening approaches have shown that OVCAR-4 exhibits distinct intracellular staining patterns and intensity kinetics when exposed to diverse fluorescent probes, enabling its classification alongside other ovarian cancer cell lines. These phenotypic signatures reflect underlying biochemical and morphological features, supporting the use of OVCAR-4 in systems biology, drug screening, and cancer cell lineage identification studies. |
|---|---|
| Organismo | Human |
| Tejido | Metastatic |
| Enfermedad | High grade ovarian serous adenocarcinoma |
| Lugar de metástasis | Ascites |
| Sinónimos | OVCAR 4, NIH:OVCAR-4, NIH:OVCAR4, OVCAR.4, OVCAR4, Ovcar4 |
Características
| Edad | 42 years |
|---|---|
| Género | Female |
| Origen étnico | Caucasian |
| Propiedades de crecimiento | Adherent |
Datos normativos
| Referencia | OVCAR-4 (Cytion catalog number 305912) |
|---|---|
| Nivel de bioseguridad | 1 |
| NCBI_TaxID | 9606 |
| N.º de acceso de Cellosaurus | CVCL_1627 |
Datos biomoleculares
| Perfil mutacional | Mutation: p.Leu130Val, Homozygous |
|---|
Manejo
| Medio de cultivo | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suplementos | Supplement the medium with 20% FBS and 0.25 units/mL human insulin |
| Reactivo de disociación | Accutase |
| Tiempo de duplicación | 34 hours ; 43 hours ; 41.4 hours |
| Densidad de siembra | 1.5 to 3 x 104 cells/cm2 |
| Renovación de fluidos | 2 to 3 times per week |
| Medio de congelación | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Descongelación y cultivo de células |
|
| Atmósfera de incubación | 37°C, 5% CO2, humidified atmosphere. |
| Condiciones de envío | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condiciones de almacenamiento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Control de calidad y análisis molecular
| Lugar de metástasis: | Ascites |
|---|
Certificado de análisis (CoA)
| Número de lote | Tipo de certificado | Fecha | Número de catálogo |
|---|---|---|---|
| 305912-040326 | Certificado de análisis | 31. Mar. 2026 | 305912 |